Artificial Intelligence and Radiomics to Predict Hepatocellular Carcinoma Risk in Cirrhosis Patients
Closed Pre-Solicitation Posted
- Solicitation number
- 75N98026Q00779
- Agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 611310 Colleges, Universities, and Professional Schools
- PSC
- R799 Support- Management: Other
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases intends to acquire a clinical patient cohort, radiographic imaging datasets, and de-identified radiology reports from the University of Pennsylvania by July 23, 2026. No set-aside applies.
The Liver Diseases Branch is funding this acquisition through the Bench-to-Bedside and Back Award Program (Award Number 1517448) to support research using radiographic imaging and artificial intelligence to evaluate hepatocellular carcinoma risk in patients with cirrhosis and advanced liver disease. The University of Pennsylvania will provide a clinical cohort of patients who underwent liver transplantation for hepatocellular carcinoma, together with associated magnetic resonance imaging studies, radiology reports, and related clinical data necessary for research analysis and model development. The research focuses on improving prediction of liver cancer risk, evaluating liver cancer recurrence following curative therapy, and supporting translational research related to liver disease and liver cancer.
NAICS 611310 (Colleges, Universities, and Professional Schools) applies.
Notice text
The mission of the National Institute of Diabetes and Digestive and Kidney Diseases is to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases to improve people’s health and quality of life.
The Liver Diseases Branch is conducting research using radiographic imaging and artificial intelligence to evaluate liver cancer risk in patients with advanced liver disease or cirrhosis. Funding for this effort was awarded through the Bench-to-Bedside and Back Award Program (Award Number 1517448). A portion of the awarded funding will be used to acquire a clinical patient cohort, associated radiographic imaging datasets, and de-identified radiology reports from the University of Pennsylvania.
The research focuses on the use of imaging data and artificial intelligence to improve prediction of liver cancer risk, evaluate liver cancer recurrence following curative therapy, and support translational research related to liver disease and liver cancer. To support these research objectives, the University of Pennsylvania will provide a clinical cohort of patients who underwent liver transplantation for hepatocellular carcinoma, together with associated magnetic resonance imaging studies, radiology reports, and related clinical data necessary for research analysis and model development.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Quantitative Analysis of Longitudinal MR Images | Office of Logisitics and Acquisition Operations | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity